Celcuity
Develops targeted cancer therapies for patients with cancers involving the PAM pathway
Highlights
- New on EvolcAdded 2026-11-14
About Celcuity
Celcuity is a biotechnology company developing targeted cancer therapies involving the PI3K/AKT/mTOR (PAM) pathway. Its first approved product, REVTORPYK (gedatolisib), is used to treat HR+/HER2-, PIK3CA wild-type advanced breast cancer in the United States.
The company is evaluating REVTORPYK in clinical trials for breast and prostate cancer, including global Phase 3 trials for first-line breast cancer treatment. Its open roles span clinical development, pharmaceutical development and operations, program management, and research and development.
Product: Develops and commercializes REVTORPYK (gedatolisib), a targeted cancer therapy, and evaluates it in clinical trials.
Jobs at Celcuity
Open roles at Celcuity in the Americas (1)
United States 1. From Celcuity's careers page or applicant tracking system; each role links to the employer.
- Senior Medical Director, Clinical Development · United States
More biotech & pharma companies
Celea Therapeutics
Develops investigational therapies for serious respiratory diseases, including idiopathic pulmonary fibrosisNew on EvolcCellanome
Live-cell imaging and single-cell transcriptomics platform for biology research labs and biopharma companiesNew on EvolcCellarity
AI and multi-omics drug discovery of oral medicines that correct dysfunctional cell states in complex diseasesNew on EvolcCellular Intelligence
Develops AI and biology approaches to engineer cell fate for biomedical and drug-development applicationsNew on EvolcCentrillion Technologies
High-density DNA chips and molecular measurement platforms for life science researchers and diagnostic partnersNew on EvolcChai Discovery
AI-based molecular design tools for pharmaceutical and life sciences companies developing medicinesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Website resourcedeclared script/iframe or software asset
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Privacy & consent
- CookiebotHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
